Resonant Capital Advisors LLC Sells 77,434 Shares of Pfizer Inc. $PFE

Resonant Capital Advisors LLC trimmed its position in shares of Pfizer Inc. (NYSE:PFE) by 55.9% during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 61,057 shares of the biopharmaceutical company’s stock after selling 77,434 shares during the quarter. Resonant Capital Advisors LLC’s holdings in Pfizer were worth $1,714,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds also recently made changes to their positions in the company. Vermillion Wealth Management Inc. boosted its holdings in Pfizer by 19.4% during the first quarter. Vermillion Wealth Management Inc. now owns 2,352 shares of the biopharmaceutical company’s stock worth $66,000 after purchasing an additional 382 shares during the last quarter. Triad Wealth Partners LLC grew its position in Pfizer by 1.9% in the 4th quarter. Triad Wealth Partners LLC now owns 20,466 shares of the biopharmaceutical company’s stock worth $510,000 after purchasing an additional 386 shares in the last quarter. Eagle Capital Management LLC increased its stake in Pfizer by 0.3% in the 1st quarter. Eagle Capital Management LLC now owns 126,573 shares of the biopharmaceutical company’s stock valued at $3,554,000 after buying an additional 390 shares during the last quarter. ETF Store Inc. increased its stake in Pfizer by 3.8% in the 4th quarter. ETF Store Inc. now owns 10,913 shares of the biopharmaceutical company’s stock valued at $272,000 after buying an additional 396 shares during the last quarter. Finally, Mattern Wealth Management LLC lifted its position in shares of Pfizer by 4.6% during the 4th quarter. Mattern Wealth Management LLC now owns 9,161 shares of the biopharmaceutical company’s stock worth $228,000 after buying an additional 400 shares in the last quarter. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Pfizer Stock Performance

PFE traded up $0.42 during midday trading on Tuesday, reaching $24.14. The company had a trading volume of 15,695,431 shares, compared to its average volume of 42,643,270. The company has a debt-to-equity ratio of 0.67, a quick ratio of 0.94 and a current ratio of 1.25. The stock has a market cap of $137.61 billion, a PE ratio of 18.42 and a beta of 0.35. Pfizer Inc. has a 12-month low of $23.11 and a 12-month high of $28.75. The business has a 50-day moving average price of $25.63 and a two-hundred day moving average price of $26.23.

Pfizer (NYSE:PFE) last released its earnings results on Tuesday, May 5th. The biopharmaceutical company reported $0.75 earnings per share for the quarter, beating analysts’ consensus estimates of $0.72 by $0.03. Pfizer had a net margin of 11.83% and a return on equity of 19.44%. The firm had revenue of $14.45 billion during the quarter, compared to the consensus estimate of $13.84 billion. During the same period in the prior year, the firm earned $0.92 EPS. The company’s revenue was up 5.4% compared to the same quarter last year. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. On average, sell-side analysts expect that Pfizer Inc. will post 2.99 earnings per share for the current fiscal year.

Pfizer Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 1st. Shareholders of record on Friday, July 24th will be issued a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a yield of 7.1%. The ex-dividend date of this dividend is Friday, July 24th. Pfizer’s dividend payout ratio is 131.30%.

Pfizer News Summary

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Pfizer won FDA approval for a new IBRANCE use in HR-positive, HER2-positive metastatic breast cancer, adding a fresh clinical and commercial catalyst that could support future sales. Pfizer (PFE) Wins FDA Approval For IBRANCE In HER2 Positive Breast Cancer
• Positive Sentiment: Several articles highlighted Pfizer as a “dirt cheap” healthcare stock, suggesting value investors may see upside if the company can stabilize growth and capitalize on its cash-generating franchise. Pfizer or AstraZeneca: Which Stock Offers Better Long-Term Potential?
• Positive Sentiment: Cantor Fitzgerald reiterated a neutral rating with a $27 price target, implying meaningful upside from recent trading levels and showing Wall Street still sees room for recovery. Benzinga rating note
• Neutral Sentiment: Pfizer Limited announced its annual meeting and proposed a final dividend, but this appears related to a different Pfizer entity and is unlikely to affect Pfizer Inc. shares. Pfizer Limited Sets July 28 Virtual AGM, Proposes Rs 75 Final Dividend
• Neutral Sentiment: Comparisons with AstraZeneca and Alnylam mostly reinforce the view that Pfizer faces stronger near-term growth questions than some peers, but these pieces are more comparative than company-specific. Pfizer or AstraZeneca: Which Stock Offers Better Long-Term Potential?
• Negative Sentiment: Analysts downgraded Pfizer to Hold, citing delayed pipeline catalysts, management changes, and weaker near-term rerating potential, which likely weighed on the stock. Pfizer’s Growth Story Faces a Wait as Pipeline and Leadership Doubts Mount
• Negative Sentiment: Pfizer was also described as sinking while the broader market advanced, reflecting continued investor concern about its growth outlook and keeping pressure on shares. Pfizer (PFE) Stock Sinks As Market Gains: Here’s Why

Analysts Set New Price Targets

PFE has been the topic of a number of research analyst reports. Royal Bank Of Canada upgraded Pfizer from an “underperform” rating to a “sector perform” rating and set a $25.00 target price on the stock in a research note on Tuesday, June 9th. Cantor Fitzgerald reaffirmed a “neutral” rating and set a $27.00 price target on shares of Pfizer in a research report on Monday. Weiss Ratings upgraded Pfizer from a “hold (c-)” rating to a “hold (c)” rating in a report on Wednesday, May 6th. Guggenheim boosted their price objective on Pfizer from $35.00 to $36.00 and gave the stock a “buy” rating in a research report on Tuesday, March 24th. Finally, Bank of America reduced their price objective on Pfizer from $27.00 to $26.00 and set a “neutral” rating for the company in a research note on Thursday, April 9th. One investment analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, thirteen have given a Hold rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus price target of $28.59.

Pfizer Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.